Cleveland Clinic Expands AD's New Therapies Donanemab and Lecanemab

Both therapies represent the first disease-modifying treatments for Alzheimer’s available in the UK in over two decades, offering renewed hope for adults with mild cognitive impairment or mild dementia due to Alzheimer’s. These offerings build on Cleveland Clinic London’s commitment to innovative, patient-centred neurological care, delivering access to transformative treatments for those affected by Alzheimer’s.